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Background: Diclofenac increases the risk of anastomotic leakage, but the underlying mechanism is
unknown. As diclofenac is excreted largely as biliary metabolites, the aim of this study was to determine
the effect of these metabolites on intestinal anastomoses.
Methods: This was a randomized controlled blinded experiment using 210 male Wistar rats to assess
the effect of ‘diclofenac bile’ on the anastomotic complication score, leak rate and anastomotic strength
following oral and parenteral administration of diclofenac. Bile duct and duodenal catheterization
techniques were used for diversion and replacement of bile, and biliary diclofenac metabolites were
determined.
Results: Replacement of control bile with diclofenac bile resulted in higher anastomotic complication
scores (P= 0⋅006) and leakage in five of 18 animals, compared with one of 18 controls (P= 0⋅089). In
turn, following oral diclofenac administration, replacement of diclofenac bile with control bile reduced
anastomotic complications (P=0⋅016). The leak rate was seven of 15 versus 13 of 17 without replacement
(P= 0⋅127). After intramuscular administration of diclofenac, the reduction in anastomotic complications
was not significant when bile was replaced with control bile (P=0⋅283), but it was significant when
bile was drained without replacement (P=0⋅025). Diclofenac metabolites in bile peaked within 2h
after administration. Administration of diclofenac bile resulted in nearly undetectable plasma levels of
diclofenac (mean(s.d.) 0⋅01(0⋅01)𝛍g/ml) after 120min. Following oral diclofenac, bile replacement with
control bile did not affect the plasma concentration of diclofenac (0⋅12(0⋅08)𝛍g/ml versus 0⋅10(0⋅05)𝛍g/ml
with diclofenac bile; P= 0⋅869).
Conclusion: Altered bile composition as a result of diclofenac administration increases the ileal anasto-
motic complication rate in rats.
Surgical relevance
Diclofenac is thought to increase the risk of intestinal anastomotic
leakage, but the underlying mechanism is unknown. Metabolites
of diclofenac are excreted largely through bile.
Using bile transfer techniques, it is shown that expo-
sure to bile from rats treated with diclofenac increases the
number of anastomotic complications. That properties of bile and
intraluminal drug concentrations are relevant for anastomotic
healing is a novel perspective on the pathophysiology of leak-
age. Further clarification of related pathways could lead to tar-
geted reduction of drug toxicity and reduction of the anastomotic
leak rate.
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Introduction
Anastomotic leakage is the leading cause of morbidity and
mortality after intestinal surgery, with leak rates varying
from 3 to 14 per cent1. Non-steroidal anti-inflammatory
drugs (NSAIDs) have been related to increased leak
rates in both animal and retrospective human studies2–4.
This is worrisome because NSAIDs are recommended as
postoperative analgesics in current guidelines5. Clinical
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evidence is not considered sufficient to ban postoperative
use of NSAIDs, as some studies do not report adverse
effects5,6. Further research is required to delineate the role
of NSAIDs in clinical anastomotic leakage4,7.
The main mechanism by which NSAIDs are believed
to jeopardize anastomotic healing is the cyclo-oxygenase
(COX) 2 inhibitory action, which may cause suppression
of inflammatory, proliferative or proangiogenic pathways
relevant for normal wound healing2,8. An alternative
explanation could be direct toxicity of intraluminal factors
resulting fromNSAID treatment (such as drug metabolites
and bile products). This is based on a similar relationship
found between NSAIDs and small intestinal mucosal
damage9–11.
It is hypothesized that the NSAID diclofenac may dis-
play its detrimental effect on bowel anastomoses through
altered and toxic bile composition. At least three observa-
tions support this hypothesis. First, NSAID-induced
intestinal mucosal damage has been attributed to
increased bile toxicity12–15. Biliary excretion of toxic
drug metabolites and reduced availability of protective
phosphatidylcholine in bile due to competitive binding
by NSAID metabolites appear to be responsible for the
bile toxicity9,12,13,16. Second, diclofenac causes leakage of
anastomoses in the ileum and proximal colon, but not in
the distal colon of the rat, which can be explained by the
fact that most bile components are reabsorbed or con-
verted to non-toxic substances before reaching the distal
colon17. Third, NSAIDs that are predominantly excreted
through bile (such as diclofenac, celecoxib and carpro-
fen) cause 80–100 per cent leakage of experimental ileal
anastomoses, whereas naproxen, which is excreted almost
entirely through urine in the rat and human, results in
less than 15 per cent leakage18–20. In clinical practice, bile
toxicity could pose a threat to a large number of patients, as
it could be harmful for both small and large bowel anasto-
moses, considering the altered physiology following partial
colectomy.
The aim of this study was to investigate the effect of
altered bile composition induced by diclofenac on small
bowel anastomotic healing in rats using bile drainage and
bile replacement techniques.
Methods
The study was carried out according to the ARRIVE
guidelines21. It was approved by the Animal Ethics Com-
mittee (AECnumber 2013-171) and performed in theCen-
tral Animal Laboratory of Radboud University.
Animals
In total, 210 adult male Wistar rats (mean(s.d.) weight
313(25) g; Harlan, Horst, The Netherlands) were used
(138 to assess anastomotic healing and 72 to donate bile).
The animals were acclimatized to laboratory conditions
and initially housed, two per cage, at 22–23∘C with a
12-h day cycle, and free access to standard rodent chow
(Ssniff® R/M-H; Bio Services, Uden, The Netherlands)
and acidified tap water throughout the experiment. The
cages were enriched with a rat retreat and nesting material,
and were placed randomly on the shelves. All animals
were checked at least twice daily. Humane endpoints were
defined; animals were killed if they showed signs of severe
discomfort (such as weight loss greater than 20 per cent,
distended abdomen or severely reduced activity).
Materials
Diclofenac sodium (DCF) (Cayman Chemical, Ann
Arbor, Michigan, USA) dissolved in 0⋅1 per cent
polysorbate in saline (sodium chloride 0⋅9 per cent)
was used for administration by oral gavage, and as a
standard for high-performance liquid chromatography
(HPLC) and liquid chromatography–mass spectrometry
(LC–MS) analyses. DCF injection fluid (25mg/ml;
Centrafarm, Etten-Leur, The Netherlands) diluted
with saline to 3⋅33mg/ml was used for intramuscu-
lar injections. 4-Hydroxydiclofenac (4OH-DCF) and
5-hydroxydiclofenac (5OH-DCF) (Toronto Research
Chemicals, Toronto, Ontario, Canada), and diclofenac
acyl-β-glucuronide (DAG) (LGC Standards, Wesel,
Germany) were used as standards for LC–MS analyses,
and diclofenac-d4 (phenyl-d4-acetic) (J. H. Ritmeester,
Nieuwegein, The Netherlands) was used as an internal
standard for bile and plasma.
Study design
The study consisted of three experiments (Table 1). A distal
ileum anastomosis model was used in all experiments and
rats had surgery on day 0; anastomotic healing was assessed
after killing on day 317. This interval was used becausemost
diclofenac-induced leakage occurs before day 3, when the
anastomosis is at its weakest, and postponing killing would
increase suffering20. Rats received 1⋅5mg/kg diclofenac
twice daily either orally (O+) or intramuscularly (IM+),
or they received no oral or intramuscular diclofenac (O−
or IM−). Cannulation of the common bile duct (CBD)
and the duodenum was performed to drain and infuse
bile respectively (Fig. 1). Allocation to groups was done
randomly by using the online tool at www.randomization
.com.
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Table 1 Experimental setup and groups
Group name No. in group* Diclofenac administration Bile drainage and replacement
Experiment 1
O−B− 18 None Bile drained and replaced by ‘control bile’ from donor rats
O−B+ 18 None Bile drained and replaced by ‘diclofenac bile’ from donor rats
O+B− 151,2,3 Oral Bile drained and replaced by ‘control bile’ from donor rats
O+B+ 173 Oral Bile drained and replaced by ‘diclofenac bile’ from donor rats
Experiment 2
IM+B= 18 Intramuscular No bile drainage or reinfusion
IM+B0 12 Intramuscular Bile drained; no bile reinfused
IM−B0 114 None Bile drained; no bile reinfused
Experiment 3
IM+B+ 12 Intramuscular Bile drained and reinfused instantly (rat receives its own bile)
IM+B− 104,5 Intramuscular Bile replaced with ‘control bile’ from donors
*Each superscript number denotes an animal that died during or just after operation. These were not included in the statistical analysis. Causes of death
were: 1intraoperative bleeding of portal vein; 2anaesthetic overdose; 3catheter displacement; 4unknown cause; 5failure of bile duct cannulation.
In experiment 1, 72 rats were allocated to four groups
of 18 each, and 72 rats were used as matched bile donors.
In group O−B−, no diclofenac was administered and bile
was drained and replaced by control bile from matched
donor rats. In group O−B+ rats, the bile was replaced
by ‘diclofenac bile’ from donor rats that had also received
1⋅5mg/kg diclofenac orally twice daily for 3 days. Rats in
groupO+B−were administered diclofenac orally, and their
bile was replaced with control bile17. Rats in group O+B+
were given diclofenac orally and received diclofenac bile
from donors.
In experiments 2 and 3, a parenteral route of diclofenac
administration was used to explore the effect of avoiding
exposure of the gut to drug molecules as a direct result
of oral administration13,14. In experiment 2, 42 rats were
allocated to three groups. Rats in group IM+B= (n= 18)
received diclofenac intramuscularly, and no cannulations of
the bile duct or duodenum were done. In groups IM+B0
and IM−B0 (n= 12 animals each), bile was drained com-
pletely without replacing it to prevent diclofenac metabo-
lites and bile salts from entering the gut. In experiment
3, rats were given diclofenac intramuscularly and either
received their own diclofenac bile (group IM+B+; n= 12)
or bile was replaced with control bile from donor rats
(group IM+B−; n= 12).
Operative procedures
All operations were done by two experienced researchers.
For analgesia, 0⋅02mg/kg buprenorphine (Temgesic®;
Schering-Plough, Houten, The Netherlands) was given
subcutaneously every 12 h, starting 1 h before the opera-
tion until 48 h afterwards. No antibiotics were given and
animals were not fasted. Anaesthesia was with isoflurane
(Abbott, Hoofddrop, The Netherlands), 5 per cent for
induction and 2⋅5–3⋅5 per cent for maintenance, in a 1 : 1
mixture of oxygen and pressurized air. Rats were pre-
pared by shaving, skin disinfection with iodine and sterile
covers, and then operated on through a 4–5-cm midline
laparotomy using strict aseptic technique under a micro-
scope (Wild M650; Wild Heerbrugg, Gais, Switzerland,
at 10–16× magnification). Body temperature was kept at
38∘C with a heating pad and lamp.
The procedures started with cannulation of the CBD to
drain bile and placement of a catheter in the duodenum
to readminister bile, if applicable. This was followed by
construction of the bowel anastomosis. The laparotomy
wound was closed with a running suture, 3/0 Vicryl®
(Ethicon, Amersfoort, The Netherlands) for the fascia and
staples for the skin.
Bile drainage and infusion techniques
The CBD was ligated with 7/0 silk (Pearsalls, Taunton,
UK) just before it enters the tail of the pancreas, and
a V-shaped hole was made in the duct with iridectomy
scissors proximal to the ligation. A custom-made 3-Fr
polyurethane cannula (BTPU-040; Instech Laboratories,
Plymouth Meeting, Pennsylvania, USA), 20 cm in length,
and a silicone ring (BTSIL-047; Instech Laboratories)
at 7 and 50mm from the sharpened tip, was inserted
into the bile duct and fixed with 7/0 silk proximal and
distal to the silicon ring at 7mm. A similar, but blunt,
cannula was inserted through a purse-string suture (6/0
Vicryl®; Ethicon, Norderstedt, Germany) in the duo-
denum. Cannulas were fixed to the abdominal wall (6/0
Vicryl®), tunnelled through the rectus muscle and subcu-
taneously towards the back between the scapulas, and then
connected to a harness (VAHD95AB or VAHD115AB;
Instech Laboratories). In turn, the harness was connected
to a tether and swivel system (VAH95T+375/22PS
or VAHD115T+375/D/22 with BTCOEX-22 tubing;
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Fig. 1 Schematic illustration of the experimental model used in
experiments 1 and 3. In experiment 2, in groups IM+B0 and
IM−B0, no bile was reinfused. IM, intramuscular; +, with
diclofenac; −, without diclofenac; B0, bile drained and not
returned
Instech Laboratories), through which the bile was trans-
ferred to 50-ml tubes in a cooled (0–10∘C) polystyrene
box. When attached to the swivel, rats were still able to
move within the entire cage and use nesting material.
In experiment 1, the tube with donor bile was changed
twice daily and kept at 4∘C until reinfusion the next day.
Because the donor rats in experiment 1 also provided the
control bile for experiment 3, and this experiment was
conducted later, the bile was kept at−80∘Cuntil reinfusion.
Because it involved control bile, there was no concern for
loss of toxicity. Bile was infused into the duodenal cannula
at room temperature (22–23∘C) using a 20-ml syringe and
an infusion pump (IVAC Medical Systems, San Diego,
California, USA) at a rate of 0⋅7–1⋅0ml/h.
Intestinal anastomosis
Anastomoses were created as described previously17.
Briefly, 1 cm of ileum was resected at 15 cm proximal
to the caecum. An inverted anastomosis was made with
a single layer of eight interrupted (Lembert) sutures
(8/0 Ethilon®; Ethicon, Norderstedt, Germany). After
operation, rats were housed individually because they were
attached to the swivel system.
Assessment of outcome
Animals were killed by asphyxiation with a mixture of
95 per cent carbon dioxide and 5 per cent oxygen, and
thereafter 100 per cent carbon dioxide (donor rats), or
by cardiac or inferior vena cava puncture combined with
cervical dislocation under general anaesthesia with isoflu-
rane (experimental rats). A relaparotomy was done and
the anastomosis was inspected macroscopically for anasto-
motic complications by a researcher blinded to the group
randomization.
Signs were graded according to the anastomotic compli-
cation score: 0, no abnormality; 1, small (less than 2mm)
anastomotic abscess; 2, free pus or large abscess; 3, faecal
peritonitis or visible dehiscence17. Grade 2 or 3 was con-
sidered an overt anastomotic leak.
Bursting pressure and breaking strength were assessed as
described previously17. Briefly, bursting pressure (mmHg)
was determined by infusing anastomotic segments with
blue fluid and measuring the maximum pressure sus-
tained before leakage occurred. Subsequently, segments
were pulled apart with a tensiometer and the highest force
measured before rupture was recorded as breaking strength
(newtons).
Analysis of diclofenac excretion profile in bile
To determine whether and when diclofenac products are
found in bile, bile samples from four donor rats were
obtained fractionally every hour after a single dose of
diclofenac 1⋅5mg/kg orally and analysed by HPLC; for
methods used see Appendix S1 (supporting information).
Quantitation of diclofenac metabolites in bile
and plasma
Bile samples were obtained as described above and analysed
by LC–MS/MS to determine which diclofenac metabo-
lites were most abundant, and when. Plasma samples were
collected in experiment 1 to assess whether bile replace-
ment with either diclofenac bile or control bile influenced
plasma concentrations through the enterohepatic circula-
tion. Samples of 1ml were drawn from the tail vein on post-
operative day 2, either at 60, 90 or 120min after diclofenac
administration. Any change in plasma level was expected
to occur after 60min, based on biliary excretion time. For
a description of methods used, see Appendix S1 (supporting
information).
Statistical analysis
Sample size was determined with expected leak rates of
70–80 per cent in groups receiving diclofenac bile and
10–20 per cent in groups receiving control bile or no
bile17. Anticipating analysis of leak rates with Fisher’s exact
test, and anticipating a larger loss to follow-up in the first
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 220–228
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Fig. 2 Anastomotic healing assessed by: a anastomotic complication scores, b anastomotic leakage, c bursting pressure (n= 5 in group
IM+B+, n= 4 in group IM+B−, due to sensor failure) and d breaking strength. O, oral; IM, intramuscular; +, with diclofenac; −,
without diclofenac; B+, bile from rats given diclofenac; B−, bile from control rats; B0, bile drained and not returned; B=, normal bile
circulation. *P< 0⋅050 (Mann–Whitney U test); †P< 0⋅050 (independent t test)
experiment, 18 animals per group were used in experiment
1 and in group IM+B= of experiment 2, and 12 animals
in other groups. Absolute leak rates, and not anastomotic
complication scores, were used because this facilitates
better sample size calculations. The Mann–Whitney U
test was used to compare complication scores, and an
independent t test to compare strength. Spread of data
is presented as the standard deviation. P< 0⋅050 was
considered statistically significant. Statistical analysis was
performed with IBM SPSS® Statistics version 22 (IBM,
Armonk, New York, USA).
Results
Animal mortality and welfare
One rat in group O+B+ and two in IM+B+ were killed
before day 3 because of severe illness due to peritonitis
(humane endpoint). Other rats had a normal postoperative
recovery or had signs of illness starting on day 3, just before
killing. Six rats (3 in group O−B−, 2 in group O+B−, and 1
in group O+B+) had to be anaesthetized to relieve cannula
obstruction by manipulating the subcutaneous part of the
catheter (leakage occurred in the 2 rats in group O+B−).
Two rats (1 in group O−B− and 1 donor rat) required a
relaparotomy to relieve intra-abdominal cannula kinking.
Postoperative weight loss in experiment 1 was com-
parable between groups (mean(s.d.) 9⋅8(2⋅8) per cent).
In experiment 2, weight loss was significantly higher in
groups where bile was not replaced (IM+B0: 13⋅7(4⋅4)
per cent; IM−B0: 14⋅8(3⋅0) per cent) compared with loss
in group IM+B=, where bile was replaced (10⋅0(2⋅6) per
cent; P= 0⋅007 and P< 0⋅001 respectively). In experiment
3, weight loss was higher in group IM+B− than in group
IM+B+ (14⋅6(2⋅7) versus 8⋅3(3⋅0) per cent respectively;
P< 0⋅001).
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Anastomotic complication score and leak rate
In experiments 1, 2 and 3, anastomotic complication scores
were the highest in ‘diclofenac bile’ groups (O−B+ ver-
sus O−B−, P= 0⋅006; O+B+ versus O+B−, P= 0⋅016;
IM+B= versus IM+B0, P= 0⋅025; IM+B+ versus IM+B−,
P= 0⋅283) (Fig. 2a). Grades 2 and 3, which were considered
leakage, occurred in five of 18 animals (28 per cent) after
administration of diclofenac bile (O−B+), compared with
one of 18 (6 per cent) with control bile (O−B−) (P= 0⋅089).
Most leakage occurred in groups receiving oral or intra-
muscular diclofenac combined with diclofenac bile: 13 of
17 animals (76 per cent) in group O+B+ versus seven of
15 (47 per cent) in group O+B− (P= 0⋅127); 12 of 18
(67 per cent) in group IM+B= versus three of 12 (25 per
cent) in group IM+B0 (P= 0⋅060); and six of 12 (50 per
cent) in group IM+B+ versus two of ten (20 per cent) in
group IM+B− (P= 0⋅117) (Fig. 2b). No leakage occurred
in group IM−B0 (P= 0⋅122 versus IM+B0; P= 0⋅001 versus
IM+B=).
Anastomotic strength
Bursting pressures corresponded with leak rates; values
tended to be lower in groupswith higher leak rates in exper-
iments 1 and 3 (Fig. 2c). In experiments 1 and 2, breaking
strength was the highest in groups that received neither
oral or intramuscular diclofenac nor diclofenac bile, with
no significant differences (Fig. 2d). A significant difference
was observed between group IM+B= and group IM+B0
(mean(s.d.) 0⋅17(0⋅09) versus 0⋅31(0⋅15)N respectively;
P= 0⋅006).
Diclofenac excretion profile in bile
HPLC analysis revealed that diclofenac was detected in bile
1 h after oral administration, that levels peaked within 2 h,
and that diclofenac remained detectable in bile at least 6 h
after administration (Fig. 3a).
Bile production and analysis of diclofenac
metabolites in bile
In the donor groups, bile production was comparable at
a mean(s.d.) rate of 14⋅9(2⋅4)ml/day in control rats and
14⋅6(2⋅0)ml/day in diclofenac rats (P= 0⋅317). DAG was
the most abundant metabolite in bile pooled over 2–8 h
after oral administration (Fig. 3b). Diclofenac metabolites
were detected almost immediately after intramuscular
administration, and levels of DAG, DCF and 4OH-DCF
peaked around 2 h after administration (Fig. 3c).
Analysis of diclofenac metabolites in plasma
Administration of ‘diclofenac bile’ in group O−B+
resulted in low mean(s.d.) plasma levels of DCF
(0⋅01(0⋅01) μg/ml), 4OH-DCF (0⋅01(0⋅01) μg/ml) and
5OH-DCF (0⋅02(0⋅02) μg/ml) after 120min. 5OH-DCF
was the most prominent metabolite found in plasma sam-
ples, with levels of 0⋅35(0⋅05) μg/ml in groups O+B− and
O+B+ at 90min, followed by DCF (0⋅26(0⋅02) μg/ml) and
4OH-DCF (0⋅10(0⋅01) μg/ml). DAG was not detected.
The plasma DCF level in group O+B− at 120min was
comparable to that of group O+B+ (0⋅12(0⋅08) versus
0⋅10(0⋅05) μg/ml respectively; P= 0⋅869). The total con-
centration of DCF and metabolites combined is displayed
in Fig. 3d.
Discussion
This study has demonstrated that increased bile toxicity
due to diclofenac administration results in more anasto-
motic complications in rats. Replacing normal bile with
‘diclofenac bile’ disturbed anastomotic healing and, in turn,
replacement of diclofenac bile with control bile reduced
signs of anastomotic leakage following administration of
diclofenac. It is suggested that the increase in bile toxic-
ity is caused by biliary excretion of diclofenac metabolites
and the subsequent increase of enteral drug and metabolite
concentrations.
The composition of bile was shown to be altered rapidly
by the presence of diclofenac metabolites after both oral
and intramuscular administration. The metabolites, DAG
and unconjugated DCF in particular, rapidly enter the gut
via biliary excretion, regardless of the route of administra-
tion. It is hypothesized that these intraluminal molecules
disturb anastomotic healing. In the present study, this was
supported by the slightly higher leak rates in oral diclofenac
groups compared with those in groups with intramuscular
administration.
That altered bile composition and intraluminal drug
molecules are detrimental in small bowel anastomosis
corresponds with earlier findings17, where diclofenac
caused leakage of anastomosis in the rat ileum and prox-
imal colon, but not in the distal colon. Bile and drug
concentrations are considerably lower in the distal colon
and are known to cause most mucosal damage in the
terminal ileum13. Furthermore, sustained release forms
of diclofenac with absorption in more distal intestinal
segments appear to divert the mucosal damage from
the small to the large intestine22. Other studies10,12,13
of NSAID-induced enteropathy have also attributed
the damage to topical effects of drug molecules. Possi-
ble underlying mechanisms involve reuptake of active
© 2018 The Authors. www.bjsopen.com BJS Open 2018; 2: 220–228
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diclofenac molecules, initially causing mitochondrial
injury and cell death, and, subsequently, initiation of an
excessive inflammatory response by activation of Toll-like
receptor 4 on macrophages11,14,23. Another possibility is
that the diclofenac molecules suppress secretion of mucus,
making the anastomosis more vulnerable to leakage, as was
recently suggested by Bosmans and colleagues24. Although
diclofenac is excreted largely as DAG, this metabolite
is reactivated by bacterial glucuronidase in the terminal
ileum, where it can cause mucosal damage12,25. In the
present study, the acyl-glucuronide metabolite (DAG) was
also abundant in bile. Reactivation of this metabolite in the
gut together with biliary excretion of unconjugated forms
of diclofenac may lead to high enteral accumulation of
potentially harmful drug molecules, which may jeopardize
healing from the luminal side of the anastomosis17,25.
The finding that healing was still disturbed when
diclofenac was administered via the parenteral route and
bile was either diverted or replaced by control bile may
suggest a systemic role for diclofenac in causing anasto-
motic leakage. COX-2 inhibition is considered the main
feature of systemic diclofenac activity, and could affect
essential inflammatory and proliferative pathways8,26.
Administration of ‘diclofenac bile’ had little impact on
plasma levels of diclofenac through the enterohepatic
circulation; thus the effect of diclofenac bile could not be
explained by more potent systemic activity.
A valid model was used to study comprehensively the
effect of diclofenac and bile composition on the most clin-
ically relevant outcome: anastomotic complications. Com-
parison of leak severity showed significant differences;
comparison of absolute leak rates did not. However, leak
rate trends pointed in the same direction. Scoring leakage
according to severity and clinical consequences is currently
advised in the literature27. The lack of significance may
have been the result of a slightly smaller effect size than
expected from previous studies; the greatest difference was
42 per cent, compared with 50 per cent expected.
The daily amount of bile produced in rats of about
12–16ml is comparable to the amount in humans of
250–1000ml per day when adjusted for body surface
area. Biliary excretion of diclofenac is poorly studied in
humans and depends on genetic polymorphisms in drug
metabolism, but is reported to be somewhat lower in
humans than in rats28. After oral administration (the pre-
ferred prescription form of diclofenac) and excretion in
bile, total diclofenac concentrations could reach compara-
ble levels in the human gut for anastomotic injury.
Bile toxicity would have most effect on anastomoses that
comprise the terminal ileum, where bile is reabsorbed
and concentrations are higher, compared with large bowel
anastomoses. However, considering the physiological
changes that occur following partial or subtotal colectomy,
bile toxicity could be comparably relevant for colorectal
anastomoses. Clinical cohort studies2–4,8 reporting an
increased risk of leakage following NSAID administration
involved both ileocolic and colorectal anastomoses.
The relevance of the properties of bile and possibly intra-
luminal drug concentrations in relation to anastomotic
healing is a novel perspective on leakage pathophysiology,
and underlying mechanisms should be further elucidated.
Current evidence provided by retrospective clinical studies
and animal models makes it ethically controversial to study
NSAIDs in a prospective randomized trial29, and exper-
imental studies are suggested to clarify further the role
of intraluminal diclofenac metabolite concentrations, the
influence of bile salts, and the role of other drug metabo-
lites, such as those of ketorolac and ibuprofen, in leakage
pathophysiology.
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